← Leaderboards
Colleen Doyle Cooper
Celdara Medical, Llc
$3,827,502
Attributed
$3,827,502
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,827,502 · 3
By mechanism
R44$3,526,912 · 2
R43$300,590 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Dose”
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Suma Babu · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Dawn Fallacara · Battelle Centers/Pub Hlth Res & Evaluatn$13,673,728
Research focus
DoseMedicalPersonsDrug KineticsClinicToxic EffectVirusCessation Of LifePharmaceutical PreparationsHourInfectionToxicologySecurityMutationInvestmentsInnovationLifeMortalityCenters For Disease Control And Prevention (U.S.)Therapeutic CandidateHospitalizationDomestic FowlsCovid-19 PandemicDisease Outbreaks
Grant awards (5)
Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma$1,228,902
R44 · FY2025 · CA · contact PI
Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas$998,375
R44 · FY2024 · AI · contact PI
Preclinical development of an important, broad-spectrum antibody for pandemic influenza$999,635
R44 · FY2023 · AI · contact PI
Development of a broad spectrum antimicrobial to combat chronic lung infection$300,590
R43 · FY2022 · HL · contact PI
Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas$300,000
R44 · FY2022 · AI · contact PI